Please provide your email address to receive an email when new articles are posted on . Among patients with low baseline HBsAg, 39% achieved HBsAg loss with tobevibart/elebsiran, which rose to 46% ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Up to 19% of patients who received JNJ-3989 achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results